Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions

Pharmacology and Therapeutics

Volumn 140, Issue 3, 2013, Pages 306-318

  Murray, Danielle ^a   Stoessl, A Jon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Depression; Neurobiological mechanisms; Neurological conditions; Pain; Parkinson's disease; Placebo effect

Indexed keywords

DOPAMINE; PLACEBO; TRYPTOPHAN HYDROXYLASE 2;

ADDICTION; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ANALGESIC ACTIVITY; ANTERIOR CINGULATE; ANTICIPATION; ARTICLE; BOLD SIGNAL; BRAIN DEPTH STIMULATION; CAUDATE NUCLEUS; CHRONIC PAIN; CLINICAL PRACTICE; CONDITIONING; CORPUS STRIATUM; DEPRESSION; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; ELECTROENCEPHALOGRAPHY; EPILEPSY; EXPECTATION; FIBROMYALGIA; FOLLOW UP; FRONTAL CORTEX; FRONTAL OPERCULUM; GRAY MATTER; HAWTHORNE EFFECT; HUMAN; HUNTINGTON CHOREA; HYPERACTIVITY; INSULA; MAJOR DEPRESSION; MENTAL DISEASE; META ANALYSIS (TOPIC); MIGRAINE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROTRANSMITTER RELEASE; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PAIN; PARIETAL CORTEX; PARKINSON DISEASE; PLACEBO EFFECT; POSTERIOR CINGULATE; POSTOPERATIVE PAIN; PREFRONTAL CORTEX; PRIMARY SOMATOSENSORY CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY PERIOD; REMISSION; RESTLESS LEGS SYNDROME; REWARD; SCHIZOPHRENIA; SENSORIMOTOR CORTEX; SOCIAL DESIRABILITY; SOCIAL INTERACTION; SOMATOSENSORY CORTEX; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMIC NUCLEUS; TACTILE STIMULATION; TENSION HEADACHE; THALAMUS LATERAL NUCLEUS; THALAMUS NUCLEUS; TREATMENT OUTCOME; TREATMENT RESPONSE;

AD; ADHD; ALZHEIMER'S DISEASE; ATTENTION DEFICIT HYPERACTIVITY DISORDER; BLOOD OXYGEN LEVEL DEPENDENT; BOLD; DEPRESSION; FMRI; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HD; HUNTINGTON'S DISEASE; MS; MULTIPLE SCLEROSIS; NEUROBIOLOGICAL MECHANISMS; NEUROLOGICAL CONDITIONS; PAIN; PARKINSON'S DISEASE; PD; PET; PLACEBO EFFECT; POSITRON EMISSION TOMOGRAPHY; RACC; RANDOMIZED CONTROLLED TRIAL; RCBF; RCT; REGIONAL CEREBRAL BLOOD FLOW; RESTLESS LEGS SYNDROME; RLS; ROSTRAL ANTERIOR CINGULATE CORTEX;

ANIMALS; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; PLACEBO EFFECT;

EID: 84885475993     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.07.009     Document Type: Review

References (156)

1. O. Agid, S. Kapur, L. Warrington, A. Loebel, and C. Siu Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders Schizophr Res 102 2008 241 248
2. A. Albanese Cell therapy for Parkinson's disease: have the glory days gone? Lancet Neurol 10 2011 492 493
3. R.P. Allen, D. Picchietti, W.A. Hening, C. Trenkwalder, A.S. Walters, and J. Montplaisi Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health Sleep Med 4 2003 101 119
4. M. Amanzio, and F. Benedetti Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems J Neurosci 19 1999 484 494
5. M. Amanzio, F. Benedetti, and L. Vase A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment Int Psychogeriatr 24 2012 698 707
6. M. Amanzio, A. Pollo, G. Maggi, and F. Benedetti Response variability to analgesics: a role for non-specific activation of endogenous opioids Pain 90 2001 205 215
7. L.Y. Atlas, R.A. Whittington, M.A. Lindquist, J. Wielgosz, N. Sonty, and T.D. Wager Dissociable influences of opiates and expectations on pain J Neurosci 32 2012 8053 8064
8. A. Autret, D. Valade, and S. Debiais Placebo and other psychological interactions in headache treatment J Headache Pain 13 2012 191 198
9. E.H. Bae, W.H. Theodore, F. Fregni, R. Cantello, A. Pascual-Leone, and A. Rotenberg An estimate of placebo effect of repetitive transcranial magnetic stimulation in epilepsy Epilepsy Behav 20 2011 355 359
10. F. Benedetti The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia Pain 64 1996 535 543
11. F. Benedetti Mechanisms of placebo and placebo-related effects across diseases and treatments Annu Rev Pharmacol Toxicol 48 2008 33 60
12. F. Benedetti Placebo responses in animals Pain 153 2012 1983 1984
13. F. Benedetti, and M. Amanzio The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin Prog Neurobiol 52 1997 109 125
14. F. Benedetti, M. Amanzio, R. Rosato, and C. Blanchard Non-opioid placebo analgesia is mediated by CB1 cannabinoid receptors Nat Med 17 2011 1228 1230
15. F. Benedetti, E. Carlino, and A. Pollo How placebos change the patient's brain Neuropsychopharmacology 36 2011 339 354
16. F. Benedetti, M. Amanzio, S. Vighetti, and G. Asteggiano The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect J Neurosci 26 2006 12014 12022
17. F. Benedetti, C. Arduino, S. Costa, S. Vighetti, L. Tarenzi, and I. Rainero Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective Pain 121 2006 133 144
18. F. Benedetti, L. Colloca, E. Torre, M. Lanotte, A. Melcarne, and M. Pesare Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus Nat Neurosci 7 2004 587 588
19. F. Benedetti, M. Lanotte, L. Colloca, A. Ducati, M. Zibetti, and L. Lopiano Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response J Physiol 587 2009 3869 3883
20. F. Benedetti, M. Lanotte, L. Lopiano, and L. Colloca When words are painful: unraveling the mechanisms of the nocebo effect Neuroscience 147 2007 260 271
21. F. Benedetti, H.S. Mayberg, T.D. Wager, C.S. Stohler, and J.-K. Zubieta Neurobiological mechanisms of the placebo effect J Neurosci 25 2005 10390 10402
22. F. Benedetti, A. Pollo, L. Lopiano, M. Lanotte, S. Vighetti, and I. Rainero Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses J Neurosci 23 2003 4315 4323
23. U. Bingel, V. Wanigasekera, K. Wiech, R. Ni Mhuircheartaigh, M.C. Lee, and M. Ploner The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil Sci Transl Med 3 70ra14 2011 1 11
24. H. Brody, and F.G. Miller Lessons from recent research about the placebo effect - from art to science J Am Med Assoc 306 2011 2612 2613
25. F. Cauda, D.M.-E. Torta, K. Sacco, E. Geda, F. D'Agata, and T. Costa Shared "core" areas between the pain and other task-related networks PLoS One 7 e41929 2012 1 10
26. M.S. Cepeda, J.A. Berlin, C.Y. Gao, F. Wiegand, and D.R. Wada Placebo response changes depending on the neuropathic pain syndrome: results of a systematic review and meta-analysis Pain Med 13 2012 575 595
27. P.D. Cohen, T. Isaacs, P. Willocks, L. Herman, J. Stamford, and S. Riggare Sham neurosurgical procedures: the patient's perspective Lancet Neurol 11 2012 1022
28. B.A. Cohen, and V.M. Rivera PRISMS: the story of a pivotal clinical trial series in multiple sclerosis Curr Med Res Opin 26 2010 827 838
29. L. Colloca, and F. Benedetti Placebos and painkillers: is mind as real as matter? Nat Rev Neurosci 6 2005 545 552
30. L. Colloca, and D. Finniss Nocebo effects, patient-clinician communication, and therapeutic outcomes J Am Med Assoc 307 2012 567 568
31. L. Colloca, P. Petrovic, T.D. Wager, M. Ingvar, and F. Benedetti How the number of learning trials affects placebo and nocebo responses Pain 151 2010 430 439
32. L. Colloca, M. Sigaudo, and F. Benedetti The role of learning in nocebo and placebo effects Pain 136 2008 211 218
33. E. Cubo, M. Gonzalez, I. del Puerto, J.G. de Yebenes, O.F. Arconda, and J.M. Gabriel y Galan Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease Mov Disord 27 2012 439 442
34. M. de la Cruz, D. Hui, H.A. Parsons, and E. Bruera Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer Cancer 116 2010 766 774
35. R. de la Fuente-Fernández The placebo-reward hypothesis: dopamine and the placebo effect Parkinsonism Relat Disord 15S3 2009 S72 S744
36. R. de la Fuente-Fernández The powerful pre-treatment effect: placebo responses in restless legs syndrome trials Eur J Neurol 19 2012 1305 1310
37. R. de la Fuente-Fernández, A.G. Phillips, M. Zamburlini, V. Sossi, D.B. Calne, and T.J. Ruth Dopamine release in human ventral striatum and expectation of reward Behav Brain Res 136 2002 359 363
38. R. de la Fuente-Fernández, T.J. Ruth, V. Sossi, M. Schulzer, D.B. Calne, and A.J. Stoessl Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease Science 293 2001 1164 1166
39. R. de la Fuente-Fernández, M. Schulzer, and A.J. Stoessl Placebo mechanisms and reward circuitry: clues from Parkinson's disease Biol Psychiatry 56 2004 67 71
40. N.J. Diederich, and C.G. Goetz The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies Neurology 71 2008 677 684
41. F. Drago, A. Nicolosi, V. Micale, and G. Lo Menzo Placebo affects the performance of rats in models of depression: is it a good control for behavioral experiments? Eur Neuropsychopharmacol 11 2001 209 213
42. A. Dumitriu, and B.O. Popescu Placebo effects in neurological diseases J Med Life 3 2010 114 121
43. F. Eippert, J. Finsterbusch, U. Bingel, and C. Büchel Direct evidence for spinal cord involvement in placebo analgesia Science 326 2009 404
44. S. Elsenbruch, V. Kotsis, S. Benson, C. Rosenberger, D. Reidick, and M. Schledowski Neural mechanisms mediating the effects of expectation in visceral placebo analgesia: an fMRI study in healthy placebo responders and nonresponders Pain 153 2012 382 390
45. P. Enck, F. Benedetti, and M. Schedlowski New insights into the placebo and nocebo responses Neuron 59 2008 195 206
46. P. Enck, U. Bingel, M. Schedlowski, and W. Rief The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 12 2013 191 204
47. V. Faria, M. Fredrikson, and T. Furmark Imaging the placebo response: a neurofunctional review Eur Neuropsychopharmacol 18 2008 473 485
48. H. Feldman, S. Gauthier, J. Hecker, B. Vellas, P. Subbiah, and E. Whalen A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease Neurology 57 2001 613 620
49. H.L. Fields, A.I. Basbaum, and M.M. Heinricher Central nervous system mechanisms of pain modulation Wall and Melzack's Textbook of Pain 2006 Elsevier London 125 152
50. D.G. Finniss, and F. Benedetti Mechanisms of the placebo response and their impact on clinical trials and clinical practice Pain 114 2005 3 6
51. D.G. Finniss, T.J. Kaptchuk, F. Miller, and F. Benedetti Biological, clinical, and ethical advances of placebo effects Lancet 375 2010 686 695
52. C.D. Fiorillo, P.N. Tobler, and W. Schultz Discrete coding of reward probability and uncertainty by dopamine neurons Science 299 2003 1898 1902
53. G. Fricchione, and G.B. Stefano Placebo neural systems: nitric oxide, morphine and the dopamine brain reward and motivation circuitries Med Sci Monit 11 2005 54 65
54. S. Fulda, and T.C. Wetter Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies Brain 131 2008 902 917
55. T. Furmark, L. Appel, S. Henningsson, F. Ahs, V. Faria, and C. Linnman A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety J Neurosci 28 2008 13066 13074
56. W.R. Galpern, J. Corrigan-Curay, A.E. Lang, J. Kahn, D. Tagle, and R.A. Barker Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations Lancet Neurol 11 2012 643 650
57. S.S. Gill, N.K. Patel, G.R. Hotton, K. O'Sullivan, R. McCarter, and M. Bunnage Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nat Med 9 2003 589 595
58. C.G. Goetz, E. Laska, C. Hicking, D. Stat, P. Damier, and T. Muller Placebo influences on dyskinesia in Parkinson's disease Mov Disord 23 2008 700 707
59. C.G. Goetz, J. Wuu, M.P. McDermott, C.H. Adler, S. Fahn, and C.R. Freed Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions Mov Disord 23 2008 690 699
60. K. Goldapple, Z. Segal, C. Garson, M. Lau, P. Bieling, and S. Kennedy Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy Arch Gen Psychiatry 61 2004 34 41
61. R.L. Gollub, and J. Kong For placebo effects in medicine, seeing is believing Sci Transl Med 3 70 ps5 2011 1 5
62. R.E. Gross, R.L. Watts, R.A. Hauser, R.A. Bakay, H. Reichmann, and R. von Kummer Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial Lancet Neurol 10 2011 509 519
63. A.B. Guekht, A.D. Korczyn, I.B. Bondareva, and E.I. Gusev Placebo responses in randomized trials of antiepileptic drugs Epilepsy Behav 17 2010 64 69
64. J.-Y. Guo, X.-Y. Yuan, F. Sui, W.-C. Zhang, and J.-Y. Wang Placebo analgesia affects the behavioral despair tests and hormonal secretions in mice Psychopharmacology 21 2011 83 90
65. J.A. Hashmi, A.T. Baria, M.N. Baliki, L. Huang, T.J. Schnitzer, and A. Vania Apkarian Brain networks predicting placebo analgesia in a clinical trial for chronic back pain Pain 153 2012 2393 2402
66. W. Häuser, E. Bartram-Wunn, C. Bartram, H. Reinecke, and T. Tölle Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy - magnitude and patient-related predictors Pain 152 2011 1709 1717
67. G.A. Hoffman, A. Harrington, and H.L. Fields Pain and the placebo: what we have learned Perspect Biol Med 48 2005 248 265
68. A. Hróbjartsson, and P.C. Gøtzsche Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment N Engl J Med 344 2001 1594 1602
69. A. Hróbjartsson, and P.C. Gøtzsche Wampold et al.'s reiterate spin in the conclusion of a re-analysis of placebo versus no-treatment trials despite similar results as in original review J Clin Psychol 63 2007 405 408
70. A. Hróbjartsson, and P.C. Gøtzsche Placebo interventions for all clinical conditions Cochrane Database Syst Rev 1 2010 CD003974
71. J. Hughes, M. Gabbay, E. Funnell, and C. Dowrick Exploratory review of placebo characteristics reported in randomised placebo controlled antidepressant drug trials Pharmacopsychiatry 45 2012 20 27
72. Huntington Study Group Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial Neurology 66 2006 366 372
73. L.D. Jacobs, R.W. Beck, J.H. Simon, R.P. Kinkel, C.M. Brownscheidle, and T.J. Murray Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis N Engl J Med 343 2000 898 904
74. K.B. Jensen, T.J. Kaptchuk, I. Kirsch, J. Raicek, K. Lindstrom, and C. Berna Nonconscious activation of placebo and nocebo pain responses Proc Natl Acad Sci U S A 109 2012 15959 15964
75. V. Kaasinen, S. Aalto, K. Någren, and J.O. Rinne Expectation of caffeine induces dopaminergic responses in humans Eur J Neurosci 19 2004 2352 2356
76. M.G. Kaplitt, A. Feigin, C. Tang, H.L. Fitzsimons, P. Mattis, and P.A. Lawlor Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial Lancet 369 2007 2097 2105
77. T.J. Kaptchuk, J.M. Kelley, L.A. Conboy, R.B. Davis, C.E. Kerr, and E.E. Jacobson Components of placebo effect: randomized controlled trial in patients with irritable bowel syndrome BMJ 336 2008 999 1003
78. T.J. Kaptchuk, J.M. Kelley, A. Deykin, P.M. Wayne, L.C. Lasagna, and I.O. Epstein Do "placebo responders" exist? Contemp Clin Trials 29 2008 587 595
79. S. Kapur, T. Arenovich, O. Agid, R. Zipursky, S. Lindborg, and B. Jones Evidence for onset of antipsychotic effects within the first 24 hours of treatment Am J Psychiatry 162 2005 939 946
80. A. Katsnelson Why fake it? How "sham" brain surgery could be killing off valuable therapies for Parkinson's disease Nature 476 2011 142 144
81. S.Y.H. Kim, R. Wilson, H.M. Kim, R.G. Holloway, R.G. De Vries, and S.A. Frank Comparison of enrollees and decliners of Parkinson disease sham surgery trials Mov Disord 27 2012 506 511
82. I. Kirsch Conditioning, expectancy, and the placebo effect: comment on Stewart-Williams and Podd Psychol Bull 130 2004 344 345
83. I. Kirsch, and G. Sapirstein Listening to prozac but hearing placebo: a meta-analysis of antidepressant medication Prev Treat 1 1998 2a
84. S. Klosterhalfen, and P. Enck Neurophysiology and psychobiology of the placebo response Curr Opin Psychiatry 21 2008 189 195
85. K.B. Knox, and M.E. Kelly Placebo power Tech Vasc Interv Radiol 15 2012 150 152
86. L. Koban, M. Brass, M.T. Lynn, and G. Pourtois Placebo analgesia affects brain correlates of error processing PLoS One 7 e49784 2013 1 8
87. J. Kong, R.L. Gollub, G. Polich, I. Kirsh, P. LaViolette, and M. Vangel A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect J Neurosci 28 2008 13354 13362
88. J. Kong, K. Jensen, R. Loiotile, A. Cheetham, H.-Y. Wey, and Y. Tan Functional connectivity of the frontoparietal network predicts cognitive modulation of pain Pain 154 2013 459 467
89. P. Krummenacher, V. Candia, G. Folkers, M. Schedlowski, and G. Schönbächler Prefrontal cortex modulates placebo analgesia Pain 148 2010 368 374
90. H.A. Landsberger Hawthorne Revisited: Management and the Worker: Its Critics, and Developments in Human Relations in Industry 1958 Cornell University Ithaca
91. A.E. Lang, W. Langston, A.J. Stoessl, M. Brodsky, D.J. Brooks, and V. Dhawan GDNF in treatment of Parkinson's disease: response to editorial Lancet Neurol 5 2006 200 202
92. A.F. Leuchter, I.A. Cook, E.A. Witte, M. Morgan, and M. Abrams Changes in brain function of depressed subjects during treatment with placebo Am J Psychiatry 159 2002 122 129
93. J. Levine The mechanism of placebo analgesia Lancet 654-657 1978
94. P.A. LeWitt, A.R. Rezai, M.A. Leehey, S.G. Ojermann, A.W. Flaherty, and E.N. Eskandar AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial Lancet Neurol 10 2011 309 319
95. S.C. Lidstone, R. de la Fuente-Fernandez, and A.J. Stoessl The placebo response as a reward mechanism Semin Pain Med 3 2005 37 42
96. S.C. Lidstone, M. Schulzer, K. Dinelle, E. Mak, V. Sossi, and T.J. Ruth Effects of expectation on placebo-induced dopamine release in Parkinson disease Arch Gen Psychiatry 67 2010 857 865
97. S.C. Lidstone, and A.J. Stoessl Understanding the placebo effect: contributions from neuroimaging Mol Imaging Biol 9 2007 176 185
98. J. Lilja Blood oxygenation level-dependent visualization of synaptic relay stations of sensory pathways along the neuroaxis in response to graded sensory stimulation of a limb J Neurosci 26 2006 6330 6336
99. F. Lui, L. Colloca, D. Duzzi, D. Anchisi, F. Benedetti, and C.A. Porro Neural bases of conditioned placebo analgesia Pain 151 2010 816 824
100. P.S. Lyby, P.M. Aslaksen, and M.A. Flaten Variability in placebo analgesia and the role of fear of pain - an ERP study Pain 152 2011 2405 2412
101. P.S. Lyby, J.T. Forsberg, O. Asli, and M.A. Flaten Induced fear reduces the effectiveness of a placebo intervention on pain Pain 153 2012 1114 1121
102. W.J. Marks, R.T. Bartus, J. Siffert, C.S. Davis, A. Lozano, and N. Boulis Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial Lancet Neurol 9 2010 1164 1172
103. W.J. Marks, J.L. Ostrem, L. Verhagen, P.A. Starr, P.S. Larson, and R.A.E. Bakay Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial Lancet Neurol 7 2008 400 408
104. H.S. Mayberg, J.A. Silva, S.K. Brannan, J.L. Tekell, R.K. Mahurin, and S. McGinnis The functional neuroanatomy of the placebo effect Am J Psychiatry 159 2002 728 737
105. W.V. McCall, R. D'Agostino, P.B. Rosenquist, J. Kimball, K. Boggs, and B. Lasater Dissection of the factors driving the placebo effect in hypnotic treatment of depressed insomniacs Sleep Med 12 2011 557 564
106. C. McRae, E. Cherin, T.G. Yamazaki, G. Diem, A.H. Vo, and D. Russell Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial Arch Gen Psychiatry 61 2004 412 420
107. K. Meissner, U. Bingel, L. Colloca, T.D. Wager, A. Watson, and M. Arve Flaten The placebo effect: advances from different methodological approaches J Neurosci 31 2011 16117 16124
108. R. Melzack, and P.D. Wall Pain mechanisms: a new theory Pain Forum 5 1965 3 11
109. R. Mercado, C. Constantoyannis, T. Mandat, A. Kumar, M. Schulzer, and A.J. Stoessl Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation Mov Disord 21 2006 1457 1461
110. D.D. Mitsikostas, L.I. Mantonakis, and N.G. Chalarakis Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches Cephalalgia 31 2011 550 561
111. D.L. Morton, A. Watson, W. El-Deredy, and A.K.P. Jones Reproducibility of placebo analgesia: effect of dispositional optimism Pain 146 2009 194 198
112. T.A. Nolan, D.D. Price, R.M. Caudle, N.P. Murphy, and J.K. Neubert Placebo-induced analgesia in an operant pain model in rats Pain 153 2012 2009 2016
113. B.S. Oken Placebo effects: clinical aspects and neurobiology Brain 131 2008 2812 2823
114. Once Weekly Interferon for MS Study Group (OWIMS) Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS study Neurology 53 1999 679 686
115. G. Pacheco-López, H. Engler, M.-B. Niemi, and M. Schedlowski Expectations and associations that heal: immunomodulatory placebo effects and its neurobiology Brain Behav Immun 20 2006 430 446
116. M. Peciña, H. Azhar, T.M. Love, T. Lu, B.L. Fredrickson, and C.S. Stohler Personality trait predictors of placebo analgesia and neurobiological correlates Neuropsychopharmacology 1-8 2012
117. C.M. Peralta, B. Frauscher, K. Seppi, E. Wolf, G.K. Wenning, and B. Hogl Restless legs syndrome in Parkinson's disease Mov Disord 24 2009 2076 2080
118. G.L. Petersen, N.B. Finnerup, K.N. Norskov, K. Grosen, H.K. Pilegaard, and F. Benedetti Placebo manipulations reduce hyperalgesia in neuropathic pain Pain 153 2012 1292 1300
119. P. Petrovic, T. Dietrich, P. Fransson, J. Andersson, K. Carlsson, and M. Ingvar Placebo in emotional processing - induced expectations of anxiety relief activate a generalized modulatory network Neuron 46 2005 957 969
120. P. Petrovic, E. Kalso, E.K. Petersson, J. Andersson, P. Fransson, and M. Ingvar A prefrontal non-opioid mechanism in placebo analgesia Pain 150 2010 59 65
121. P. Petrovic, E. Kalso, K.M. Petersson, and M. Ingvar Placebo and opioid analgesia - imaging a shared neuronal network Science 295 2002 1737 1740
122. D. Pietrobon, and M.A. Moskowitz Pathophysiology of migraine Annu Rev Physiol 75 2013 365 391
123. A. Pollo, and F. Benedetti The placebo response: neurobiological and clinical issues of neurological relevance Prog Brain Res 175 2009 283 294
124. A. Pollo, E. Carlino, and F. Benedetti Placebo mechanisms across different conditions: from the clinical setting to physical performance Philos Trans R Soc Lond B Biol Sci 366 2011 1790 1798
125. A. Pollo, E. Carlino, L. Vase, and F. Benedetti Preventing motor training through nocebo suggestions Eur J Appl Physiol 112 2012 3893 3903
126. D.D. Price Psychological and neural mechanisms of the affective dimension of pain Science 288 2000 1769 1772
127. D.D. Price, D.G. Finniss, and F. Benedetti A comprehensive review of the placebo effect: recent advances and current thought Annu Rev Psychol 59 2008 565 590
128. D.D. Price, R. Staud, M.E. Robinson, A.P. Mauderli, R. Cannon, and C.J. Vierck Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients Pain 99 2002 49 59
129. P. Rainville Brain mechanisms of pain affect and pain modulation Curr Opin Neurobiol 12 2002 195 204
130. V.P. Reddy, M. Kozielska, M. Johnson, A. Vermeulen, R. de Greef, and J. Liu Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders Clin Pharmacokinet 50 2011 429 450
131. I.H. Richard, M.P. McDermott, R. Kurlan, J.M. Lyness, P.G. Como, and N. Pearson A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease Neurology 78 2012 1229 1236
132. W. Rief, U. Bingel, M. Schedlowski, and P. Enck Mechanisms involved in placebo and nocebo responses and implications for drug trials Nat Clin Pharmacol Ther 90 2011 722 726
133. W. Rief, and J.A. Glombiewski The hidden effects of blinded, placebo-controlled randomized trials: an experimental investigation Pain 153 2012 2473 2477
134. W. Rief, Y. Nestoriuc, S. Weiss, E. Welzel, A.J. Barsky, and S.G. Hofmann Meta-analysis of the placebo response in antidepressant trials J Affect Disord 118 2009 1 8
135. A.D. Sandler, and J.W. Bodfish Open-label use of placebos in the treatment of ADHD: a pilot study Child Care Health Dev 34 2008 104 110
136. W. Schultz Getting formal with dopamine and reward Neuron 36 2002 241 263
137. P. Schweinhardt, D.A. Seminowicz, E. Jaeger, G.H. Duncan, and M.C. Bushnell The anatomy of the mesolimbic reward system: a link between personality and the placebo analgesic response J Neurosci 29 2009 4882 4887
138. D.J. Scott, C.S. Stohler, C.M. Egnatuk, H. Wang, R.A. Koeppe, and J.-K. Zubieta Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses Arch Gen Psychiatry 65 2008 220 231
139. N. Stein, C. Sprenger, J. Scholz, K. Wiech, and U. Bingel White matter integrity of the descending pain modulatory system is associated with interindividual differences in placebo analgesia Pain 153 2012 2210 2217
140. N.P. Stover, and R.L. Watts Spheramine for treatment of Parkinson's disease Neurotherapeutics 5 2008 252 259
141. A. Strafella, J.H. Ko, and O. Monchi Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation Neuroimage 31 2006 1666 1672
142. A.P. Strafella, T. Paus, J. Barrett, and A. Dagher Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus J Neurosci 21 2001 RC157
143. A.P. Strafella, T. Paus, M. Fraraccio, and A. Dagher Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex Brain 126 2003 2609 2615
144. E.L. Thorndike A constant error in psychological ratings J Appl Psychol 4 1920 25 29
145. I. Tracey Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans Nat Med 16 2010 1277 1283
146. P.C. Trimmer, J.A.R. Marshall, L. Fromhage, J.M. McNamara, and A.I. Houston Understanding the placebo effect from an evolutionary perspective Evol Hum Behav 34 2012 8 15
147. L. Vase, M.E. Robinson, G.N. Verne, and D.D. Price Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms Pain 115 2005 338 347
148. F.J. Vingerhoets, M. Schulzer, D.B. Calne, and B.J. Snow Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 41 1997 58 64
149. B.A. Vogt Pain and emotion interactions in subregions of the cingulate gyrus Nat Rev Neurosci 6 2005 533 544
150. N.D. Volkow, G.-J. Wang, Y. Ma, J.S. Fowler, C. Wong, and M. Jayne Neuroimage 32 2006 1782 1792
151. N.D. Volkow, G.-J. Wang, Y. Ma, J.S. Fowler, W. Zhu, and L. Maynard J Neurosci 23 2003 11461 11468
152. T.D. Wager, L.Y. Atlas, L.A. Leotti, and J.K. Rilling Predicting individual differences in placebo analgesia: contributions of brain activity during anticipation and pain experience J Neurosci 31 2011 439 452
153. T.D. Wager, and H. Fields Placebo analgesia. Ed. 6. Wall and Melzack's Textbook of Pain 2013 Churchill Livingstone Philadelphia
154. T.D. Wager, J.K. Rilling, E.E. Smith, A. Sokolik, K.L. Casey, and R.J. Davidson Placebo-induced changes in FMRI in the anticipation and experience of pain Science 303 2004 1162 1167
155. R.R. Zhang, W.C. Zhang, J.Y. Wang, and J.Y. Guo The opioid placebo analgesia is mediated exclusively through μ-opioid receptor in rat Int J Neuropsychopharmacol 25 2012, Jul 1 8
156. J.-K. Zubieta, and C.S. Stohler Neurobiological mechanisms of placebo responses Ann N Y Acad Sci 1156 2009 198 210